Vaxcyte Net Income Over Time
| PCVX Stock | USD 54.98 0.59 1.06% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Vaxcyte Performance and Vaxcyte Correlation. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vaxcyte. Anticipated expansion of Vaxcyte directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Vaxcyte assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Vaxcyte requires distinguishing between market price and book value, where the latter reflects Vaxcyte's accounting equity. The concept of intrinsic value - what Vaxcyte's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Vaxcyte's price substantially above or below its fundamental value.
It's important to distinguish between Vaxcyte's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Vaxcyte should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Vaxcyte's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Net Income Analysis
Compare Vaxcyte and related stocks such as Crispr Therapeutics, Arrowhead Pharmaceuticals, and PTC Therapeutics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CRSP | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (25.8 M) | (23.2 M) | (68.4 M) | (165 M) | 66.9 M | (348.9 M) | 377.7 M | (650.2 M) | (153.6 M) | (366.3 M) | (329.6 M) | (313.1 M) |
| ARWR | (854.5 K) | (21.1 M) | (31.1 M) | (58.6 M) | (91.9 M) | (81.7 M) | (34.4 M) | (54.5 M) | 68 M | (84.6 M) | (140.8 M) | (176.5 M) | (205.3 M) | (599.5 M) | (1.6 M) | (1.5 M) | (1.5 M) |
| PTCT | 30.9 M | 30.9 M | (26.2 M) | (51.6 M) | (93.8 M) | (170.4 M) | (142.1 M) | (79 M) | (128.1 M) | (251.6 M) | (438.2 M) | (523.9 M) | (559 M) | (626.6 M) | (363.3 M) | (327 M) | (343.3 M) |
| KRYS | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (7.9 M) | (10.9 M) | (19.1 M) | (32.2 M) | (69.6 M) | (140 M) | 10.9 M | 89.2 M | 102.5 M | 107.7 M |
| TGTX | (3.6 M) | (853.1 K) | (18.1 M) | (20.5 M) | (55.8 M) | (62.9 M) | (78.3 M) | (118.5 M) | (173.5 M) | (172.9 M) | (279.4 M) | (348.1 M) | (223.8 M) | 12.7 M | 23.4 M | 21 M | 22.1 M |
| ALKS | (40.1 M) | 25 M | 25 M | 17.6 M | (30.1 M) | (227.2 M) | (208.4 M) | (157.9 M) | (139.3 M) | (196.6 M) | (110.9 M) | (48.2 M) | (158.3 M) | 355.8 M | 367.1 M | 422.1 M | 443.2 M |
| CRNX | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (9.2 M) | (27.1 M) | (49.5 M) | (72.9 M) | (106.7 M) | (160 M) | (214.5 M) | (298.4 M) | (268.6 M) | (255.1 M) |
| ACLX | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (18 M) | (32.1 M) | (63.9 M) | (188.7 M) | (70.7 M) | (107.3 M) | (96.6 M) | (101.4 M) |
Vaxcyte and related stocks such as Crispr Therapeutics, Arrowhead Pharmaceuticals, and PTC Therapeutics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Vaxcyte financial statement analysis. It represents the amount of money remaining after all of Vaxcyte operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Vaxcyte | PCVX |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 825 Industrial Road, |
| Exchange | NASDAQ Exchange |
USD 54.98
Additional Tools for Vaxcyte Stock Analysis
When running Vaxcyte's price analysis, check to measure Vaxcyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxcyte is operating at the current time. Most of Vaxcyte's value examination focuses on studying past and present price action to predict the probability of Vaxcyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxcyte's price. Additionally, you may evaluate how the addition of Vaxcyte to your portfolios can decrease your overall portfolio volatility.